期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Remission of type 2 diabetes mellitus
1
作者 Afif Nakhleh Elya Halfin Naim Shehadeh 《World Journal of Diabetes》 SCIE 2024年第7期1384-1389,共6页
The surge in type 2 diabetes mellitus(T2DM)is tightly linked to obesity,leading to ectopic fat accumulation in internal organs.Weight management has become a cornerstone of T2DM treatment,with evidence suggesting that... The surge in type 2 diabetes mellitus(T2DM)is tightly linked to obesity,leading to ectopic fat accumulation in internal organs.Weight management has become a cornerstone of T2DM treatment,with evidence suggesting that significant weight loss can induce remission.Remission,defined as sustained hemoglobin(HbA1c)below 6.5% for at least 3 months without medication,can be achieved through various approaches,including lifestyle,medical,and surgical interventions.Metabolic bariatric surgery offers significant remission rates,particularly for patients with severe obesity.Intensive lifestyle modifications,including lowcalorie diets and exercise,have also demonstrated significant potential.Medications like incretin-based agents show robust results in improving beta-cell function,achieving glycemic control,and promoting weight loss.While complete remission without medication may not be attainable for everyone,especially those with severe insulin resistance or deficiency,early and aggressive glycemic control remains a crucial strategy.Maintaining HbA1c below 6.5%from the time of diagnosis reduces the risk of long-term complications and mortality.Moreover,considering a broader definition of remission,encompassing individuals with sustained control on medication,could offer a more comprehensive and inclusive approach to managing this chronic disease. 展开更多
关键词 Type 2 diabetes mellitus REMISSION Lifestyle intervention Metabolic bariatric surgery Glucose-lowering medications Weight management medications
下载PDF
治疗胰高血糖素样肽-1类似物治疗2型糖尿病
2
作者 John P H Wilding Kevin Hardy +2 位作者 苏欣(译) 刘灵佳(译) 周智广(校) 《英国医学杂志中文版》 2011年第5期310-313,共4页
什么是胰高糖素样肽-1类似物? 胰高血糖素样肽-1(GLP-1)是一种天然生成的肽类激素,在进食后由肠道释放。GLP-1刺激胰岛素释放(肠促胰岛素效应),抑制胰高糖素释放(因而减少肝糖原异生),延迟胃排空以及增加饱腹感。天然GLP-1... 什么是胰高糖素样肽-1类似物? 胰高血糖素样肽-1(GLP-1)是一种天然生成的肽类激素,在进食后由肠道释放。GLP-1刺激胰岛素释放(肠促胰岛素效应),抑制胰高糖素释放(因而减少肝糖原异生),延迟胃排空以及增加饱腹感。天然GLP-1可因体内内肽酶如二肽基肽酶IV(DPP4)的作用而迅速降解,半衰期(tl/2)仅有几分钟。GLP-1类似物,同时也被称为肠促胰岛素类似物(艾塞那肽和利拉鲁肽), 展开更多
关键词 胰高血糖素样肽-1 GLP-1类似物 2型糖尿病 胰高糖素样肽-1 治疗 胰岛素类似物 肠促胰岛素 胰岛素释放
原文传递
非酒精性脂肪肝一例报道
3
作者 CJ Gardner P Richardson +5 位作者 C Wong N Polavarapu GJ Kemp DJ Cuthbertson 谷丽娟(译) 程宗佑(校) 《英国医学杂志中文版》 2011年第3期181-183,共3页
将甲状腺功能减退视为非酒精性脂肪肝的致病因素。 非酒精性脂肪肝是常见慢性肝病,患病比例逐年上升(有报道为人群的30%~40%),是肝功能异常的常见原因。非酒精性脂肪肝可引起一系列组织学改变,包括单纯的肝细胞脂肪变性和肝细... 将甲状腺功能减退视为非酒精性脂肪肝的致病因素。 非酒精性脂肪肝是常见慢性肝病,患病比例逐年上升(有报道为人群的30%~40%),是肝功能异常的常见原因。非酒精性脂肪肝可引起一系列组织学改变,包括单纯的肝细胞脂肪变性和肝细胞脂肪坏死,伴有不同程度的肝细胞纤维化,可促进肝病的进展和并发症(肝功能衰竭和肝脏肿瘤)的发生。 展开更多
关键词 非酒精性脂肪肝 肝细胞脂肪变性 甲状腺功能减退 慢性肝病 肝功能异常 组织学改变 肝功能衰竭 致病因素
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部